Argos Therapeutics Inc.announced that it plans to develop a state-of-the-art bio-manufacturing facility in Durham, North Carolina.
The nearly 100,000 sq. ft. facility will be in the Research Triangle Park area.
Argos Therapeutics will receive about $9.5 million in incentives as well as logistical and planning support from the State of North Carolina, Durham County, the City of Durham, and the North Carolina Biotechnology Center.
The incentive package from the North Carolina Department of Commerce to support the project totals $7.1 million, including a $4.5 million Job Development Investment Grant, $600,000 in education and on-the-job training assistance, a $1.8 million sales tax exemption on qualifying equipment, and a $200,000 Economic Development Award from the North Carolina Biotechnology Center.
In addition, Argos Therapeutics entered into a lease with The Keith Corp.(Charlotte, NC) to construct the facility on T.W. Alexander Drive in Durham, North Carolina.
The facility will be used to support automated production of the company’s Arcelis-based personalized immunotherapy product candidates, beginning with AGS-003, the company’s lead oncology product candidate, currently being evaluated in the pivotal ADAPT phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC), Argos Therapeutics said in a statement.